<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20531" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Diltiazem</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Talreja</surname>
            <given-names>Om</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Om Talreja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20531.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Diltiazem is an oral and parenteral non-dihydropyridine calcium channel blocker. It is used in many clinical scenarios as an antihypertensive, anti-arrhythmic, and anti-anginal. FDA-approved indications include atrial arrhythmia, hypertension, paroxysmal supraventricular tachycardia, and chronic stable angina. Diltiazem also has numerous off-label indications for migraine prophylaxis, anal fissures, and pulmonary hypertension. This activity will highlight the mechanism of action, adverse event profile, approved and off-label uses, dosing, pharmacodynamics, pharmacokinetics, relevant diltiazem interactions, and monitoring of patients treated with diltiazem. It also emphasizes the pertinent interprofessional team members' role when prescribing diltiazem for any of its intended indications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanisms of action for diltiazem.</p></list-item><list-item><p>Identify the approved and off-label indications for diltiazem use.</p></list-item><list-item><p>Review the adverse events for diltiazem therapy.</p></list-item><list-item><p>Outline the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using diltiazem.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20531&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20531">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20531.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Diltiazem is an oral and parenteral non-dihydropyridine calcium channel blocker. It is useful in many clinical scenarios as an antihypertensive, anti-arrhythmic, and anti-anginal agent.<xref ref-type="bibr" rid="article-20531.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Atrial arrhythmia, including&#x000a0;atrial fibrillation with the rapid ventricular rate (RVR)<xref ref-type="bibr" rid="article-20531.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Paroxysmal supraventricular tachycardia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic stable angina</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Angina Due to Coronary Artery Spasm(&#x000a0;Prinzmetal's or variant angina)<xref ref-type="bibr" rid="article-20531.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Diltiazem also has utility in numerous&#x000a0;off-label indications. A select few are listed below.</p>
        <p>
<bold>Non-FDA-approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anal fissures<xref ref-type="bibr" rid="article-20531.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Migraine prophylaxis<xref ref-type="bibr" rid="article-20531.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary hypertension(Group 1 Pulmonary hypertension patients with&#x000a0;positive vasoreactivity test)<xref ref-type="bibr" rid="article-20531.r6">[6]</xref><xref ref-type="bibr" rid="article-20531.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20531.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Diltiazem is a non-dihydropyridine calcium channel blocker (CCB). Therapeutic effects occur through various mechanisms. Primarily, diltiazem inhibits the inflow of calcium ions into the cardiac muscle during depolarization. Reduced intracellular calcium concentrations increase smooth muscle relaxation, resulting in arterial vasodilation and decreased blood pressure.&#x000a0;</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem primarily produces its antihypertensive effect by relaxing the vascular smooth muscle and decreasing peripheral vascular resistance. The magnitude of blood pressure reduction is related to hypertension; thus, hypertensive individuals experience an antihypertensive effect, whereas there is only a modest fall in blood pressure in normotensives.</p>
          </list-item>
        </list>
        <p>
<bold>Atrial Arrhythmia/Paroxysmal Supraventricular Tachycardia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem is a negative inotrope (decreased force) and negative chronotrope (reduced rate). Along with coronary artery vasodilation, the combination decreases myocardial oxygen demand resulting in decreased heart rate.</p>
          </list-item>
        </list>
        <p>
<bold>Angina</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem has been shown to increase exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and blood pressure at submaximal and maximal workloads. Diltiazem is a potent dilator of coronary arteries, both epicardial and subendocardial.<xref ref-type="bibr" rid="article-20531.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Diltiazem is well absorbed from the GIT and undergoes extensive first-pass metabolism; resultant bioavailability is approximately 40%.&#x000a0;The immediate-release diltiazem tablet has an onset of action of 30&#x000a0;to 60 minutes.<xref ref-type="bibr" rid="article-20531.r9">[9]</xref>&#x000a0;</p>
        <p><bold>Distribution: </bold>Diltiazem is 70% to 80% bound to plasma proteins.&#x000a0;</p>
        <p><bold>Metabolism: </bold>Diltiazem is metabolized by the cytochrome P450 system and is an inhibitor of CYP3A4, which can lead to drug-drug interactions. Desacetyl diltiazem, the metabolite of diltiazem, also contributes to coronary vasodilatation.<xref ref-type="bibr" rid="article-20531.r10">[10]</xref></p>
        <p><bold>Excretion:</bold> The plasma elimination half-life following drug administration is about 3.0 to 4.5 hours.&#x000a0;Diltiazem undergoes extensive metabolism in which 2% to 4% of the unchanged drug appears in the urine.</p>
      </sec>
      <sec id="article-20531.s4" sec-type="Administration">
        <title>Administration</title>
        <p>In the United States, diltiazem is FDA-approved as an oral immediate-release, extended-release, controlled-release (CD), and intravenous formulation. There are numerous brand names for oral&#x000a0;diltiazem&#x000a0;(capsules and tablets), and available strengths include 30 mg, 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, and 420 mg. Compounded topical preparations of diltiazem are used off-label.<xref ref-type="bibr" rid="article-20531.r11">[11]</xref><xref ref-type="bibr" rid="article-20531.r12">[12]</xref>&#x000a0;Review&#x000a0;the package insert for the formulation by brand name because pharmacokinetics vary significantly between different brands.<bold>&#x000a0;</bold></p>
        <p>Diltiazem may be confused with diazepam. The use of tall-man lettering&#x000a0;is advised to avoid this medication error as it poses a significant threat to patient safety. Hence&#x000a0;FDA and ISMP (institute of safe medical practices) have provided the name of these sound-alike look-alike drugs to avoid potential medical errors.<xref ref-type="bibr" rid="article-20531.r13">[13]</xref><xref ref-type="bibr" rid="article-20531.r14">[14]</xref></p>
        <p>The following represent the dosing variances by condition using generic names under various trade&#x000a0;names.</p>
        <p>
<bold>Recommended Dosages</bold>
</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem hydrochloride (various brands)
<list list-type="bullet"><list-item><p>Initial dose: 180 mg&#x000a0;to 240 mg once daily</p></list-item><list-item><p>Maximum dose: 480 mg once daily</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Diltiazem HCl (various brands)
<list list-type="bullet"><list-item><p>Initial dose: 120 mg&#x000a0;to 240 mg once daily</p></list-item><list-item><p>Maximum dose: 540 mg once daily</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Diltiazem HCl extended-release (various brands)
<list list-type="bullet"><list-item><p>Initial dose: 180 mg&#x000a0;to 240 mg once daily</p></list-item><list-item><p>Maximum dose: 540 mg once daily</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Chronic Stable Angina</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem hydrochloride (various brands)
<list list-type="bullet"><list-item><p>Initial dose: 30 mg four times daily*</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Diltiazem HCl (various brands)
<list list-type="bullet"><list-item><p>Initial dose: 120 mg to 180 mg once daily</p></list-item><list-item><p>Maximum dose: 480 mg once daily</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Diltiazem HCl (various brands)
<list list-type="bullet"><list-item><p>Initial dose: 120 mg&#x000a0;to 180 mg once daily</p></list-item><list-item><p>Maximum dose: 540 mg once daily</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Diltiazem HCl extended-release (various brands)*
<list list-type="bullet"><list-item><p>Initial dose: 180 mg once daily</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Diltiazem HCl extended-release (various brands)
<list list-type="bullet"><list-item><p>Initial dose: 120 mg once daily</p></list-item><list-item><p>Maximum dose: 480 mg once daily</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Atrial Arrhythmia/Paroxysmal Supraventricular Tachycardia</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial dose: IV bolus 0.25 mg/kg ABW(adjusted body weight<bold>)</bold> IV over 2 minutes
<list list-type="bullet"><list-item><p>If needed, repeat the dose at 0.35 mg/kg ABW IV after 15 minutes</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Maintenance dose: IV continuous infusion 10mg/hr
<list list-type="bullet"><list-item><p>Increase dose at 5mg/hr to max 15mg/hr</p></list-item><list-item><p>Max infusion time is 24 hours&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Renal Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No dose adjustment is necessary.</p>
          </list-item>
        </list>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No dose adjustment is likely needed for mild-moderate hepatic impairment, but diltiazem is extensively metabolized in the liver. Consequently, use with caution in hepatic impairment.<xref ref-type="bibr" rid="article-20531.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy Considerations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem is teratogenic in animals, and only limited human data exist; thus, its use is only recommended in pregnancy if the potential benefit justifies the potential risk to the fetus.<xref ref-type="bibr" rid="article-20531.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Breastfeeding Considerations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem is excreted in human milk. Based on the current data, the amounts of&#x000a0;diltiazem&#x000a0;ingested by the infant are small.&#x000a0;However, due to&#x000a0;serious adverse reactions, if diltiazem is deemed essential, the clinician should suggest an alternative method of infant feeding.<xref ref-type="bibr" rid="article-20531.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20531.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <list list-type="bullet">
          <list-item>
            <p>Common adverse effects of diltiazem therapy include peripheral edema, bradycardia, dizziness, headache,&#x000a0;and fatigue.<xref ref-type="bibr" rid="article-20531.r17">[17]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe adverse effects include congestive heart failure, myocardial infarction, and hepatotoxicity.<xref ref-type="bibr" rid="article-20531.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem is&#x000a0;indicated for treating arrhythmias and, consequently, has the potential to worsen or create new arrhythmias&#x000a0;such as extrasystole&#x000a0;and AV block.<xref ref-type="bibr" rid="article-20531.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem is extensively metabolized through the CYP450 system and requires careful medication profile review. Concomitant use alongside potent CYP450 inhibitors may increase diltiazem concentrations leading to adverse effects even at clinically recommended doses.<xref ref-type="bibr" rid="article-20531.r19">[19]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent administration with agents that slow cardiac conduction can further potentiate adverse effects like AV block or bradycardia.<xref ref-type="bibr" rid="article-20531.r20">[20]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diltiazem-associated photo-distributed hyperpigmentation has been described in case reports.<xref ref-type="bibr" rid="article-20531.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drug-Drug Interactions: Beta-blockers and diltiazem interaction may lead to bradyarrhythmias.&#x000a0;<xref ref-type="bibr" rid="article-20531.r22">[22]</xref>&#x000a0;A recent drug-drug interaction study has identified a fatality resulting from diltiazem-ibrutinib interaction. Diltiazem is a moderate inhibitor of CYP3A4, and ibrutinib is a substrate of this CYP3A4; concurrent administration for an&#x000a0;extended time decreases ibrutinib clearance and results in cardiotoxicity.<xref ref-type="bibr" rid="article-20531.r23">[23]</xref>&#x000a0;Diltiazem is also a P-glycoprotein inhibitor;&#x000a0; hence there is an increased bleeding risk associated with direct oral anticoagulants (DOACs) like dabigatran or apixaban concomitantly&#x000a0;with the &#x000a0;P-glycoprotein inhibitor diltiazem.<xref ref-type="bibr" rid="article-20531.r24">[24]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20531.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Sick sinus syndrome except in the presence of a functioning ventricular pacemaker</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe hypotension(SBP&#x0003c;90 mm hg)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Documented hypersensitivity to the drug</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute myocardial infarction and pulmonary congestion</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent administration of intravenous beta-blockers</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wide complex ventricular tachycardia<xref ref-type="bibr" rid="article-20531.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Atrial fibrillation or flutter associated with an accessory bypass tract (i.e., Wolff-Parkinson-White syndrome)<xref ref-type="bibr" rid="article-20531.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Second- or third-degree AV block except in the presence of a functioning ventricular pacemaker<xref ref-type="bibr" rid="article-20531.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiogenic shock<xref ref-type="bibr" rid="article-20531.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>According to ACC/AHA 2022 guidelines, in patients with HFrEF(heart failure with reduced ejection fraction) after acute myocardial infarction, diltiazem&#x000a0;is associated with a higher risk of recurrent HF.<xref ref-type="bibr" rid="article-20531.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Alcohol increases the rate&#x000a0;of absorption of&#x000a0;diltiazem hydrochloride. Alcohol&#x000a0;increases&#x000a0;the rate and extent of exposure to diltiazem controlled-release (CD) formulation and is associated with dose-related adverse reactions. Advise patients to&#x000a0;avoid&#x000a0;simultaneous consumption&#x000a0;of alcohol with diltiazem CD.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20531.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Therapeutic monitoring includes periodic blood pressure assessments, heart rate, and electrocardiograms. When treating hypertension and arrhythmias, objective findings assess the therapy's efficacy. In contrast, subjective&#x000a0;findings, such as a patient's&#x000a0;frequency and severity of chest pain, are used to evaluate effectiveness when treating chronic angina.</p>
        <p>A comprehensive metabolic panel is also performed at baseline to track potential changes in electrolytes and kidney and liver function.</p>
        <p>Additional monitoring is required when using diltiazem parenterally. When treating arrhythmias, an IV bolus is administered&#x000a0;over two minutes. Continuous&#x000a0;blood pressure and ECG monitoring are&#x000a0;necessary during bolus administration.&#x000a0;</p>
        <p>For the treatment of hypertension during pregnancy, recommendations state that using an alternative agent, since diltiazem has shown adverse fetal effects in animal studies. If a patient is controlled&#x000a0;on diltiazem to treat hypertrophic cardiomyopathy, diltiazem therapy may continue, but additional fetal monitoring is required.<xref ref-type="bibr" rid="article-20531.r15">[15]</xref></p>
        <p>Similarly, serum digoxin levels should be monitored with concurrent administration of diltiazem. Clinicians should monitor&#x000a0;apixaban anti-Xa assay or heparin anti-Xa assay to decide if patients require dose&#x000a0;adjustment&#x000a0;to reduce adverse events in patients prescribed apixaban and concomitant p-glycoprotein and CYP3A4 inhibitors like diltiazem with statins.<xref ref-type="bibr" rid="article-20531.r29">[29]</xref></p>
      </sec>
      <sec id="article-20531.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Diltiazem is available in many dosage forms and strengths, making it imperative to be cautious when prescribing, dispensing, and&#x000a0;administering this medication. There have been reports of diltiazem overdose in amounts ranging from &#x0003c;1 g to 18 g. In cases with the known outcome, most patients recovered, and in cases with a fatal outcome, the majority involved&#x000a0;multiple drug ingestion.&#x000a0;</p>
        <p>
<bold>Clinical Features&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Profound bradycardia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dizziness</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>End organ dysfunction&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypotension</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>AV block</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac failure</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac arrest</p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treat according to ACLS protocol for arrhythmias&#x000a0;and hypotension.<xref ref-type="bibr" rid="article-20531.r30">[30]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Whole bowel irrigation for gastrointestinal decontamination<xref ref-type="bibr" rid="article-20531.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administer IV calcium gluconate or calcium chloride.<xref ref-type="bibr" rid="article-20531.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administer IV atropine (0.60 to 1.0 mg) for bradycardia.<xref ref-type="bibr" rid="article-20531.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV glucagon&#x000a0;enhances intracellular levels of cyclic adenosine monophosphate and increases heart rate.<xref ref-type="bibr" rid="article-20531.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe toxicity may respond to&#x000a0;hyperinsulinemia/euglycemia therapy(HIET).<xref ref-type="bibr" rid="article-20531.r35">[35]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lipid emulsion therapy in significant cardiotoxicity.<xref ref-type="bibr" rid="article-20531.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transvenous pacemaker to assist with electrical conduction. If there are no contraindications, an intra-aortic balloon pump&#x000a0;can be deployed.<xref ref-type="bibr" rid="article-20531.r37">[37]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Extracorporeal membrane oxygenation is used for&#x000a0; Massive diltiazem overdose.<xref ref-type="bibr" rid="article-20531.r38">[38]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CCBs, including diltiazem, are extremely protein-bound; consequently, extracorporeal removal by hemodialysis is&#x000a0;ineffective.<xref ref-type="bibr" rid="article-20531.r39">[39]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administer vasopressors and inotropic agents&#x000a0;(e.g., dopamine or norepinephrine) for severe hypotension and cardiac failure.<xref ref-type="bibr" rid="article-20531.r40">[40]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The use of vasopressors is common in patients with diltiazem overdose and is associated with&#x000a0;promising clinical outcomes.<xref ref-type="bibr" rid="article-20531.r40">[40]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20531.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diltiazem has been widely used in practice for many clinical indications. Proper dosage and frequency are essential to enhance patient care and improve outcomes. Diltiazem possesses negative inotropic effects and is generally avoided in patients with congestive heart failure, and diltiazem is also on the Beers Criteria.<xref ref-type="bibr" rid="article-20531.r41">[41]</xref> These factors highlight the importance of avoiding diltiazem in patients with heart failure, especially in the elderly, due to drug interactions and exacerbation of heart failure.<xref ref-type="bibr" rid="article-20531.r42">[42]</xref>&#x000a0;According to the study, older adults with hypertension who are prescribed calcium channel blockers, including diltiazem, are&#x000a0;dispensed a loop diuretic at higher rates due to peripheral edema. This is an example of prescribing cascade; clinicians should re-assess the patient before prescribing a diuretic to treat peripheral edema.<xref ref-type="bibr" rid="article-20531.r43">[43]</xref>&#x000a0;[level 3]</p>
        <p>Ideally, Clinicians should verify drug, dose, and patient factors before administration. For example, one common error with diltiazem therapy is an incorrect dose administered to the patient. Double-checking doses can help ensure the patient receives appropriate therapeutic management in inpatient and outpatient settings. Pharmacists, nurses, and other providers should also check for potential drug interactions with other medications of the patient's profile. For example, diltiazem is available in many brand names with differing recommended dosages and maximum daily doses; this vigilance will limit drug interactions and incorrect dosing.&#x000a0;Nursing staff should monitor for clinical improvement and any adverse drug reactions and inform the clinicians in case of any inconsistency. If the pharmacist or nurse suspects anything is amiss, they should contact the prescriber immediately.</p>
        <p>In overdose, triage nurses and emergency department physicians should quickly stabilize the patient. Critical care physician supervision is necessary for severe hypotension and cardiac failure. IABP insertion requires cardiac consultation. Obtain the latest information by&#x000a0;contacting the poison control center (800-222-1222) in the United States. As illustrated above, clinicians (MDs, DOs, NPs, PAs), specialists, nurses, pharmacists, and other healthcare providers are involved in taking care of the patient. Hence it is vital to communicate and work collaboratively for better patient outcomes related to diltiazem therapy. An interprofessional team approach involving all the providers would maximize efficacy and minimize adverse drug reactions translating to optimal patient outcomes with minimum adverse drug reactions. [Level 5]</p>
      </sec>
      <sec id="article-20531.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20531&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20531">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20531/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20531">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20531.s11">
        <title>References</title>
        <ref id="article-20531.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiner</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of sustained-release diltiazem in stable angina pectoris.</article-title>
            <source>Am J Cardiol</source>
            <year>1986</year>
            <month>Jan</month>
            <day>01</day>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-9</page-range>
            <pub-id pub-id-type="pmid">3510525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bishop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Diltiazem Dosing Strategies in the Management of Atrial Fibrillation With Rapid Ventricular Rate.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e18829</fpage>
            <pub-id pub-id-type="pmid">34804686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <chapter-title>Diltiazem</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31643234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Acheson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scholefield</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>The role of topical diltiazem in the treatment of chronic anal fissures that have failed glyceryl trinitrate therapy.</article-title>
            <source>Colorectal Dis</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>430</fpage>
            <page-range>430-5</page-range>
            <pub-id pub-id-type="pmid">12790914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grossman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Messerli</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Calcium antagonists.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2004</year>
            <season>Jul-Aug</season>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-57</page-range>
            <pub-id pub-id-type="pmid">15517514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayeux</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>IZ</given-names>
              </name>
              <name>
                <surname>Dechand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>McKellar</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hatton</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Management of Pulmonary Arterial Hypertension.</article-title>
            <source>Curr Cardiovasc Risk Rep</source>
            <year>2021</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">33224405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vachiery</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vonk Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beghetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez Sanchez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hansmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klepetko</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pierard</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Trindade</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Zompatori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>M</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Jan</month>
            <day>01</day>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-119</page-range>
            <pub-id pub-id-type="pmid">26320113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanza</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Maseri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Coronary Artery Spasm.</article-title>
            <source>Curr Treat Options Cardiovasc Med</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-90</page-range>
            <pub-id pub-id-type="pmid">11096513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Means</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Gentry</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TT</given-names>
              </name>
            </person-group>
            <article-title>Intravenous Continuous Infusion vs. Oral Immediate-release Diltiazem for Acute Heart Rate Control.</article-title>
            <source>West J Emerg Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>417</fpage>
            <page-range>417-422</page-range>
            <pub-id pub-id-type="pmid">29560075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mircioiu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anuta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mircioiu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nicolescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fotaki</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>In Vitro-In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of its Metabolite.</article-title>
            <source>Pharmaceutics</source>
            <year>2019</year>
            <month>Jul</month>
            <day>16</day>
            <volume>11</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">31315287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knight</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Birks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farouk</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Topical diltiazem ointment in the treatment of chronic anal fissure.</article-title>
            <source>Br J Surg</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>553</fpage>
            <page-range>553-6</page-range>
            <pub-id pub-id-type="pmid">11298624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sajid</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sains</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baig</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure.</article-title>
            <source>Colorectal Dis</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-26</page-range>
            <pub-id pub-id-type="pmid">22487078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Groh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stichtenoth</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Proposal of a Tall Man Letter list for German-speaking countries.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>77</volume>
            <issue>8</issue>
            <fpage>1247</fpage>
            <page-range>1247-1249</page-range>
            <pub-id pub-id-type="pmid">33501509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>872</fpage>
            <page-range>872-884</page-range>
            <pub-id pub-id-type="pmid">29800453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>C&#x000ed;fkov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kintscher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Simoncini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>07</day>
            <volume>39</volume>
            <issue>34</issue>
            <fpage>3165</fpage>
            <page-range>3165-3241</page-range>
            <pub-id pub-id-type="pmid">30165544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Diltiazem</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de la Sierra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.</article-title>
            <source>J Hum Hypertens</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>503</fpage>
            <page-range>503-11</page-range>
            <pub-id pub-id-type="pmid">19148104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osmonov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Erdinler</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ozcan</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Altay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turkkan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hasdemir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alper</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Cakmak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Satilmis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gurkan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of patients with drug-induced atrioventricular block.</article-title>
            <source>Pacing Clin Electrophysiol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>804</fpage>
            <page-range>804-10</page-range>
            <pub-id pub-id-type="pmid">22530749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fravel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Drug Interactions with Antihypertensives.</article-title>
            <source>Curr Hypertens Rep</source>
            <year>2021</year>
            <month>Mar</month>
            <day>05</day>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">33666764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kinoshita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishiguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ouchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Minami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Utsumi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Motomura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Komeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fuke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hishida</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>An autopsy case of combined drug intoxication involving verapamil, metoprolol and digoxin.</article-title>
            <source>Forensic Sci Int</source>
            <year>2003</year>
            <month>Apr</month>
            <day>23</day>
            <volume>133</volume>
            <issue>1-2</issue>
            <fpage>107</fpage>
            <page-range>107-12</page-range>
            <pub-id pub-id-type="pmid">12742696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Diltiazem-associated Photodistributed Hyperpigmentation.</article-title>
            <source>Yale J Biol Med</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-47</page-range>
            <pub-id pub-id-type="pmid">32226335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nordin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Khelae</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study.</article-title>
            <source>J Geriatr Cardiol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>749</fpage>
            <page-range>749-759</page-range>
            <pub-id pub-id-type="pmid">27899939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falconer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carrington</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Death from diltiazem-ibrutinib interaction.</article-title>
            <source>Aust Prescr</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>107</fpage>
            <page-range>107-108</page-range>
            <pub-id pub-id-type="pmid">34211249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lesko</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>e203593</fpage>
            <pub-id pub-id-type="pmid">32329770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Callans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dickfeld</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Matlock</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Myerburg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Sep</month>
            <day>25</day>
            <volume>138</volume>
            <issue>13</issue>
            <fpage>e272</fpage>
            <page-range>e272-e391</page-range>
            <pub-id pub-id-type="pmid">29084731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>130</volume>
            <issue>23</issue>
            <fpage>2071</fpage>
            <page-range>2071-104</page-range>
            <pub-id pub-id-type="pmid">24682348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fey</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jost</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geise</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Bertsch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Christ</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman].</article-title>
            <source>Med Klin Intensivmed Notfmed</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>111</volume>
            <issue>5</issue>
            <fpage>458</fpage>
            <page-range>458-62</page-range>
            <pub-id pub-id-type="pmid">26440099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>145</volume>
            <issue>18</issue>
            <fpage>e895</fpage>
            <page-range>e895-e1032</page-range>
            <pub-id pub-id-type="pmid">35363499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ainsworth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gleaton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bookstaver</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2022</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>668</fpage>
            <page-range>668-675</page-range>
            <pub-id pub-id-type="pmid">35032137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Pozner</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Geib</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mick</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil.</article-title>
            <source>Crit Care Med</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>2071</fpage>
            <page-range>2071-5</page-range>
            <pub-id pub-id-type="pmid">17855820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thanacoody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>H&#x000f6;jer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hoppu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bedry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-12</page-range>
            <pub-id pub-id-type="pmid">25511637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.</article-title>
            <source>Emerg Med J</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>355</fpage>
            <page-range>355-7</page-range>
            <pub-id pub-id-type="pmid">12101159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Proano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blocker overdose.</article-title>
            <source>Am J Emerg Med</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>444</fpage>
            <page-range>444-50</page-range>
            <pub-id pub-id-type="pmid">7605536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahr</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Valdes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lamas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Use of glucagon for acute intravenous diltiazem toxicity.</article-title>
            <source>Am J Cardiol</source>
            <year>1997</year>
            <month>Jun</month>
            <day>01</day>
            <volume>79</volume>
            <issue>11</issue>
            <fpage>1570</fpage>
            <page-range>1570-1</page-range>
            <pub-id pub-id-type="pmid">9185662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greene</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gawarammana</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Dargan</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study.</article-title>
            <source>Intensive Care Med</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>2019</fpage>
            <page-range>2019-24</page-range>
            <pub-id pub-id-type="pmid">17622512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bologa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lionte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sorodoc</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Lipid emulsion therapy in cardiodepressive syndrome after diltiazem overdose--case report.</article-title>
            <source>Am J Emerg Med</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>1154.e3</fpage>
            <page-range>1154.e3-4</page-range>
            <pub-id pub-id-type="pmid">23685061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salhanick</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Management of calcium channel antagonist overdose.</article-title>
            <source>Drug Saf</source>
            <year>2003</year>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>65</fpage>
            <page-range>65-79</page-range>
            <pub-id pub-id-type="pmid">12534324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durward</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guerguerian</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shemie</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Massive diltiazem overdose treated with extracorporeal membrane oxygenation.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-6</page-range>
            <pub-id pub-id-type="pmid">12831424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bunchman</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kebede</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghannoum</surname>
                <given-names>M</given-names>
              </name>
              <collab>EXTRIP workgroup</collab>
            </person-group>
            <article-title>Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2021</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>361</fpage>
            <page-range>361-375</page-range>
            <pub-id pub-id-type="pmid">33555964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Padilla-Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruha</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center.</article-title>
            <source>Ann Emerg Med</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>252</fpage>
            <page-range>252-8</page-range>
            <pub-id pub-id-type="pmid">23642908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Analysis of inappropriate medication use and drug interactions in older people in South Korea&#x02029;.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>55</volume>
            <issue>11</issue>
            <fpage>847</fpage>
            <page-range>847-852</page-range>
            <pub-id pub-id-type="pmid">28853697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanlon</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Schmader</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Boult</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Artz</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Fillenbaum</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Ruby</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Garrard</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Use of inappropriate prescription drugs by older people.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-34</page-range>
            <pub-id pub-id-type="pmid">12028243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20531.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savage</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Visentin</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bronskill</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gruneir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giannakeas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luke</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Stall</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension.</article-title>
            <source>JAMA Intern Med</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>180</volume>
            <issue>5</issue>
            <fpage>643</fpage>
            <page-range>643-651</page-range>
            <pub-id pub-id-type="pmid">32091538</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
